Claudio Ronco

Claudio Ronco appears in the supplied material as the series editor of Contributions to Nephrology, specifically the series volume Hepatitis C in Renal Disease, Hemodialysis and Transplantation. Although the evidence does not provide a personal biography, clinical scene, or independent plot trajectory for him, his named position gives the book an identifiable editorial authority and places its discussion of hepatitis C within a nephrology-centered medical reference series.

Editorial Identity

Claudio Ronco is credited as the Series Editor of Contributions to Nephrology, volume 176. The front matter places his name beside Vicenza, establishing the series-level identity under which the volume is presented. This is the complete biographical information supplied about him: he is not introduced through a patient history or as the investigator in any of the studies discussed, but through the publication structure that gathers and organizes them.

The Volume He Frames

The volume concerns Hepatitis C in Renal Disease, Hemodialysis and Transplantation, and its subject matter repeatedly crosses the boundaries between infection, liver injury, kidney disease, and transplant medicine. The material distinguishes anti-HCV antibody positivity from active infection demonstrated by HCV RNA, noting that chronic infection requires both findings and that molecular assays can detect RNA at thresholds of approximately 15 IU/ml. It also emphasizes evaluation of hepatic and extrahepatic effects, including cryoglobulinemia-associated vasculitis and renal disease, with liver biopsy and noninvasive approaches such as FibroScan used to assess fibrosis.

Within this editorial frame, HCV is presented not as a narrowly hepatic condition but as a disease with systemic and institutional consequences. Mixed cryoglobulinemia is described as an HCV-associated vasculitis that may involve arthralgias, Raynaud phenomena, purpura, neuropathy, low complement levels, and kidney disease; its renal manifestations include proteinuria, hematuria, reduced estimated glomerular filtration rate, nephritic syndrome, and nephrotic syndrome. In renal allografts, HCV is linked to immune complex-mediated glomerulonephritis, de novo membranoproliferative glomerulonephritis, proteinuria, and difficult distinctions between membranoproliferative lesions and transplant glomerulopathy.

Evidence, Risk, and Patient Experience

The book's evidence-driven orientation is especially visible in its treatment of long-term dialysis. A meta-analysis of seven observational studies involving 11,589 dialysis patients found an adjusted relative risk of 1.34 for all-cause mortality among patients with anti-HCV antibodies, while the unadjusted relative risk for liver-related mortality was 5.89. Hepatocellular carcinoma and cirrhosis occurred more often as causes of death in anti-HCV-positive dialysis patients, even though another large Australian and New Zealand study suggested that many patients may die before the long-term hepatic complications of HCV become dominant.

The volume also preserves a patient-centered dimension beneath its laboratory and survival measures. HCV infection was associated with a lower mental component score on the SF-36 quality-of-life instrument in a study of 165 dialysis patients, 83 of whom were anti-HCV positive, while no association was found with the physical component score. Depression, fatigue, cognitive impairment, diagnostic labeling, and anxiety about long-term health are presented as possible pathways through which infection affects lived experience. Treatment itself carries burdens: interferon-based therapy can produce flu-like symptoms, anemia, neutropenia, depression, and anxiety, leading to dose reduction in 35–42% of patients and discontinuation in about 30%.

Screening and Transplantation

The editorial scope extends into the governance of transplant eligibility. Kidney transplant candidates with HCV require systematic screening because as many as 25% of patients with active infection may already have advanced fibrosis despite well-compensated disease. In low-prevalence settings, the recommended sequence begins with an EIA followed by nucleic acid testing for patients with positive antibody results; in high-prevalence settings, nucleic acid testing is recommended initially because a negative EIA may not reliably exclude infection.

The waiting list becomes a continuing site of surveillance rather than a one-time administrative step. Patients with positive NAT results are placed on hold and referred to a hepatologist for assessment and possible treatment. Candidates who have achieved a sustained virologic response require at least annual NAT testing to confirm that the response persists, while those who remain viremic need yearly evaluation for progression of liver disease. The cited waiting-list data show why this monitoring matters: among 13 patients who underwent repeat liver biopsy before transplantation, 8, or 62%, showed worsening liver histology, compared with 7 of 31, or 23%, after transplantation.

Editorial Significance

Ronco's significance in the evidence is therefore structural. By appearing as series editor rather than as a subject of a clinical episode, he anchors a work in which HCV is tracked across diagnostic categories, bodily systems, statistical outcomes, and institutional decisions. The resulting frame joins molecular confirmation, fibrosis assessment, dialysis mortality, quality of life, antiviral toxicity, transplant candidacy, and renal-allograft pathology into one field of nephrological inquiry.

The material does not support claims about Ronco's personal views, research findings, or development beyond this editorial credit. What it does establish is a mediating role: his name marks the series context through which the volume presents HCV as simultaneously an infection, a source of systemic disease, a determinant of survival and mental well-being, and a factor that can alter access to and outcomes after kidney transplantation.